Restoring mitochondrial health in
high-risk obesity

MTRX31 is a novel mitochondrial-targeted small molecule in preclinical development for the treatment of obesity. In a preclinical diet-induced obesity (DIO) model at thermoneutrality, intermittent treatment with MTRX31 resulted in more durable and greater body weight loss than tirzepatide (Figure A), 62.2% lower fat mass than DIO vehicle after 8 weeks (Figure B) and demonstrated that MTRX31-mediated weight loss does not involve lean mass loss (Figure C) but that MTRX31-mediated weight loss overcomes insulin resistance (Figure D). MTRX31 therapy significantly regressed liver fattiness and demonstrated an additive effect in combination with tirzepatide (Figure E).

Methods: Thermoneutral DIO model – Six-week-old male C57BL/6J mice were fed HFD (60%) or standard chow (NC) for 15 weeks and then dosed with MTRX31 (5 mg/kg; s.c. TIW), tirzepatide “TZP” (5 nmol/kg, s.c. QD), or combinations for 8 weeks (n=10). Fat and lean mass were determined by MRI. Abbreviations: TIW – Three times per week dosing frequency.  QD – Daily dosing frequency. HFD – High-fat diet.  DIO – Diet-induced obesity.  NC – lean animals fed standard chow.